Melanoma in Chile: demographics and clinico-pathological features

Simple item page
dc.coverageDOI: 10.3389/fonc.2025.1604442
dc.creatorKoch Hein, Erica C.
dc.creatorVillanueva, Francisco
dc.creatorVilbert, Maysa
dc.creatorAraya, Verónica
dc.creatorAbarzúa-Araya, Álvaro
dc.creatorAntúnez-Lay, Andrea
dc.creatorCárdenas, Consuelo
dc.creatorCastro, Juan Camilo
dc.creatorDominguez, Francisco
dc.creatorDroppelmann, Katherine
dc.creatorDroppelmann, Nicolás
dc.creatorGalindo, Héctor
dc.creatorLeón, Augusto
dc.creatorMadrid, Jorge
dc.creatorMimica, Ximena
dc.creatorMolgó, Montserrat
dc.creatorMondaca, Sebastián
dc.creatorMontero, Pablo H.
dc.creatorRomero, Diego
dc.creatorUribe, Pablo
dc.creatorVillaseca, Miguel A.
dc.creatorVinés, Eugenio
dc.creatorRichardson, Celeste
dc.creatorNavarrete-Dechent, Cristian
dc.date2025
dc.date.accessioned2026-01-05T21:18:55Z
dc.date.available2026-01-05T21:18:55Z
dc.description<p>Background: Melanoma incidence is rising globally, yet epidemiological data from Latin America remain limited. In low- and middle-income countries, such data are essential for shaping evidence-based public health strategies. Objectives: To describe the demographic, clinical, and pathological characteristics of melanoma in Chile using a multi-institutional registry. Methods: We conducted a multicenter observational cohort study including patients ≥18 years with histologically confirmed melanoma diagnosed between 2014 and 2022 at one public and one private tertiary center in Santiago. Demographic, clinical, pathological, molecular, and survival data for cutaneous melanoma were analyzed using descriptive and survival statistics. Results: A total of 1,037 patients were included, of whom 979 (94.4%) had cutaneous melanoma. Among these patients, median age was 55 years and 54.8% were female. Cutaneous melanoma was more often diagnosed at early stages, particularly in the private setting. The most frequent histopathological subtypes were superficial spreading (31.6%), nodular (17.8%), and acral lentiginous melanoma (9.3%). Self-detection was the most common mode of identification (52.8%). Among patients with stage III–IV cutaneous melanoma tested for BRAF, 47.6% were positive. Higher risk of death was associated with advanced stage, nodular or amelanotic subtypes, BRAF-mutant tumors, male sex, and age ≥65 years. Only 34.8% of patients with stage IIB–IV cutaneous melanoma received systemic therapy. Conclusion: This study offers the most comprehensive characterization of melanoma in Chile to date, underscoring survival disparities by clinical, pathological, and healthcare access factors. Findings highlight the urgent need to expand access to early detection, molecular testing, and systemic therapies.</p>eng
dc.identifierhttps://investigadores.uandes.cl/en/publications/55d71052-e1ab-400f-a61e-dd8b68a2cba3
dc.identifier.urihttps://repositorio.uandes.cl/handle/uandes/68258
dc.languageeng
dc.rightsinfo:eu-repo/semantics/openAccess
dc.sourcevol.15 (2025)
dc.subjectdiagnosis
dc.subjectimmunotherapy
dc.subjectLatin America
dc.subjectmelanoma
dc.subjectskin cancer
dc.subjectsurvival
dc.subjectSDG 3 - Good Health and Well-being
dc.titleMelanoma in Chile: demographics and clinico-pathological featureseng
dc.typeArticleeng
dc.typeArtículospa
Files
Collections
Pure-CRIS